Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Risperidone | 19 | 2018 | 61 | 7.260 |
Why?
|
| Antipsychotic Agents | 23 | 2024 | 379 | 4.720 |
Why?
|
| Bone Density | 9 | 2026 | 363 | 3.400 |
Why?
|
| Weight Gain | 10 | 2023 | 383 | 2.580 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 6 | 2026 | 238 | 2.530 |
Why?
|
| Bone and Bones | 5 | 2026 | 305 | 2.410 |
Why?
|
| Iron | 6 | 2025 | 309 | 2.340 |
Why?
|
| Sertraline | 2 | 2024 | 45 | 1.640 |
Why?
|
| Adolescent | 51 | 2025 | 20917 | 1.620 |
Why?
|
| Depression | 6 | 2024 | 1338 | 1.570 |
Why?
|
| Anxiety Disorders | 5 | 2019 | 716 | 1.520 |
Why?
|
| Anxiety | 5 | 2025 | 1002 | 1.480 |
Why?
|
| Central Nervous System Stimulants | 4 | 2026 | 128 | 1.390 |
Why?
|
| Autism Spectrum Disorder | 4 | 2025 | 437 | 1.360 |
Why?
|
| Ferritins | 5 | 2024 | 109 | 1.280 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2025 | 139 | 1.220 |
Why?
|
| Fluoxetine | 2 | 2024 | 45 | 1.100 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 2 | 2018 | 54 | 1.100 |
Why?
|
| Child | 39 | 2025 | 26239 | 1.060 |
Why?
|
| Sexual Behavior | 2 | 2021 | 245 | 1.030 |
Why?
|
| Hyperprolactinemia | 3 | 2017 | 23 | 0.920 |
Why?
|
| Puberty | 2 | 2024 | 104 | 0.910 |
Why?
|
| Basal Ganglia | 1 | 2025 | 61 | 0.890 |
Why?
|
| Absorptiometry, Photon | 8 | 2017 | 199 | 0.880 |
Why?
|
| Male | 50 | 2025 | 65158 | 0.870 |
Why?
|
| Metformin | 2 | 2023 | 167 | 0.870 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 75 | 0.840 |
Why?
|
| Metabolic Syndrome | 3 | 2014 | 362 | 0.840 |
Why?
|
| Dietary Supplements | 2 | 2025 | 453 | 0.820 |
Why?
|
| Body Height | 1 | 2024 | 196 | 0.810 |
Why?
|
| Humans | 65 | 2026 | 131504 | 0.780 |
Why?
|
| Autonomic Nervous System | 2 | 2023 | 48 | 0.770 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 327 | 0.760 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 323 | 0.760 |
Why?
|
| Female | 42 | 2025 | 71087 | 0.710 |
Why?
|
| Mental Disorders | 5 | 2019 | 901 | 0.690 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 41 | 0.690 |
Why?
|
| Young Adult | 15 | 2023 | 10092 | 0.680 |
Why?
|
| Hyperglycemia | 1 | 2023 | 234 | 0.680 |
Why?
|
| Cognition | 2 | 2025 | 842 | 0.660 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 833 | 0.660 |
Why?
|
| Migraine Disorders | 2 | 2020 | 64 | 0.650 |
Why?
|
| Movement Disorders | 1 | 2023 | 224 | 0.650 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 332 | 0.640 |
Why?
|
| Steroids | 2 | 2019 | 172 | 0.610 |
Why?
|
| Catatonia | 1 | 2019 | 18 | 0.590 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 52 | 0.580 |
Why?
|
| Body Mass Index | 11 | 2023 | 1682 | 0.580 |
Why?
|
| Cyclosporine | 1 | 2019 | 129 | 0.570 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2015 | 45 | 0.570 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3834 | 0.570 |
Why?
|
| Sexual Maturation | 1 | 2018 | 46 | 0.570 |
Why?
|
| Calcium Carbonate | 1 | 2017 | 11 | 0.550 |
Why?
|
| Cholecalciferol | 1 | 2017 | 20 | 0.540 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 16 | 0.530 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 67 | 0.520 |
Why?
|
| Antifungal Agents | 1 | 2019 | 298 | 0.500 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 81 | 0.500 |
Why?
|
| Lumbar Vertebrae | 4 | 2023 | 109 | 0.500 |
Why?
|
| Basal Ganglia Diseases | 1 | 2016 | 23 | 0.490 |
Why?
|
| Toxoplasma | 1 | 2016 | 18 | 0.480 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 22 | 0.480 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 32 | 0.480 |
Why?
|
| Bacteroidetes | 1 | 2015 | 23 | 0.470 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2023 | 856 | 0.470 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 5277 | 0.470 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 33 | 0.460 |
Why?
|
| Problem Behavior | 1 | 2016 | 39 | 0.460 |
Why?
|
| Serotonin Antagonists | 1 | 2015 | 15 | 0.460 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 886 | 0.450 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 794 | 0.450 |
Why?
|
| Comorbidity | 5 | 2023 | 1590 | 0.450 |
Why?
|
| Body Composition | 1 | 2017 | 550 | 0.430 |
Why?
|
| Gene Deletion | 1 | 2017 | 773 | 0.430 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 153 | 0.430 |
Why?
|
| Adiposity | 1 | 2015 | 207 | 0.420 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 123 | 0.420 |
Why?
|
| Electroconvulsive Therapy | 2 | 2004 | 85 | 0.390 |
Why?
|
| Pilot Projects | 5 | 2021 | 1450 | 0.390 |
Why?
|
| Prolactin | 4 | 2016 | 112 | 0.390 |
Why?
|
| Obesity | 4 | 2023 | 2379 | 0.390 |
Why?
|
| Overweight | 1 | 2016 | 377 | 0.380 |
Why?
|
| Cytokines | 1 | 2018 | 1347 | 0.380 |
Why?
|
| Bipolar Disorder | 1 | 2015 | 364 | 0.370 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 49 | 0.350 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 610 | 0.340 |
Why?
|
| Isoxazoles | 1 | 2011 | 32 | 0.340 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 6 | 0.340 |
Why?
|
| Methylphenidate | 1 | 2010 | 57 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2021 | 844 | 0.310 |
Why?
|
| Glycine | 1 | 2010 | 165 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 1624 | 0.310 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2009 | 41 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2019 | 6485 | 0.300 |
Why?
|
| Algorithms | 1 | 2015 | 1685 | 0.280 |
Why?
|
| Linear Models | 3 | 2017 | 695 | 0.280 |
Why?
|
| Leptin | 1 | 2009 | 218 | 0.280 |
Why?
|
| Treatment Outcome | 9 | 2023 | 12936 | 0.280 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2021 | 228 | 0.280 |
Why?
|
| Child, Preschool | 7 | 2018 | 15047 | 0.270 |
Why?
|
| Fractures, Bone | 2 | 2026 | 207 | 0.270 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 117 | 0.270 |
Why?
|
| Pyrimidines | 1 | 2011 | 443 | 0.270 |
Why?
|
| Emotions | 3 | 2019 | 361 | 0.250 |
Why?
|
| Fracture Healing | 1 | 2026 | 31 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1516 | 0.240 |
Why?
|
| Demography | 2 | 2017 | 243 | 0.230 |
Why?
|
| Imagination | 2 | 2008 | 14 | 0.230 |
Why?
|
| Sex Characteristics | 2 | 2017 | 338 | 0.220 |
Why?
|
| Adult | 11 | 2025 | 31666 | 0.220 |
Why?
|
| Myasthenia Gravis | 1 | 2004 | 69 | 0.210 |
Why?
|
| Methohexital | 1 | 2003 | 3 | 0.210 |
Why?
|
| Methyl Ethers | 1 | 2003 | 23 | 0.210 |
Why?
|
| Mental Processes | 1 | 2003 | 38 | 0.210 |
Why?
|
| Anesthetics, Intravenous | 1 | 2003 | 47 | 0.200 |
Why?
|
| Anesthetics, Inhalation | 1 | 2003 | 44 | 0.200 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2023 | 29 | 0.200 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 3090 | 0.200 |
Why?
|
| Quinolones | 2 | 2013 | 58 | 0.190 |
Why?
|
| Acceptance and Commitment Therapy | 2 | 2020 | 44 | 0.180 |
Why?
|
| Sex Factors | 2 | 2019 | 1345 | 0.180 |
Why?
|
| Orgasm | 1 | 2021 | 6 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2024 | 5120 | 0.180 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2021 | 11 | 0.180 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 223 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 1254 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2081 | 0.170 |
Why?
|
| Mental Health | 1 | 2024 | 382 | 0.170 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1634 | 0.170 |
Why?
|
| Hospitals, Pediatric | 1 | 2025 | 794 | 0.170 |
Why?
|
| Piperazines | 2 | 2013 | 272 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 703 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 1168 | 0.150 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 386 | 0.150 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 171 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1404 | 0.150 |
Why?
|
| Avoidance Learning | 1 | 2019 | 63 | 0.150 |
Why?
|
| Respiratory Sinus Arrhythmia | 1 | 2018 | 10 | 0.150 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 82 | 0.140 |
Why?
|
| Permeability | 1 | 2018 | 120 | 0.140 |
Why?
|
| Time Factors | 3 | 2018 | 6273 | 0.140 |
Why?
|
| Risk Factors | 4 | 2019 | 10952 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2019 | 251 | 0.140 |
Why?
|
| Prevalence | 2 | 2017 | 2692 | 0.140 |
Why?
|
| Seizures | 1 | 2003 | 889 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 2116 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 3403 | 0.140 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 37 | 0.130 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 99 | 0.130 |
Why?
|
| Hospitalization | 1 | 2025 | 1939 | 0.130 |
Why?
|
| Inflammation | 2 | 2021 | 1490 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2021 | 417 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3911 | 0.120 |
Why?
|
| Asymptomatic Infections | 1 | 2016 | 39 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 530 | 0.120 |
Why?
|
| Aggression | 2 | 2023 | 221 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 773 | 0.120 |
Why?
|
| Social Perception | 2 | 2008 | 54 | 0.120 |
Why?
|
| Iron Metabolism Disorders | 1 | 2015 | 14 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2016 | 104 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2016 | 125 | 0.120 |
Why?
|
| Brain | 2 | 2008 | 3237 | 0.120 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 64 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2016 | 244 | 0.110 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 101 | 0.110 |
Why?
|
| Blood Glucose | 3 | 2023 | 1102 | 0.110 |
Why?
|
| Logistic Models | 1 | 2019 | 1831 | 0.110 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 147 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2015 | 134 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 615 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 194 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3452 | 0.100 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2014 | 150 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 760 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1023 | 0.100 |
Why?
|
| Skinfold Thickness | 1 | 2012 | 34 | 0.090 |
Why?
|
| Prognosis | 2 | 2019 | 4951 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2024 | 4674 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17648 | 0.090 |
Why?
|
| Conduct Disorder | 1 | 2011 | 32 | 0.090 |
Why?
|
| Paliperidone Palmitate | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2011 | 4 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 713 | 0.090 |
Why?
|
| Sexual Development | 1 | 2011 | 25 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 34 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 36 | 0.080 |
Why?
|
| Calcium | 1 | 2016 | 1041 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 203 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 630 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2011 | 81 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2013 | 467 | 0.080 |
Why?
|
| Radius | 1 | 2010 | 37 | 0.080 |
Why?
|
| Growth | 1 | 2010 | 92 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 154 | 0.080 |
Why?
|
| Anthropometry | 1 | 2010 | 190 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2009 | 95 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 609 | 0.070 |
Why?
|
| United States | 1 | 2024 | 11794 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 547 | 0.070 |
Why?
|
| Child Behavior Disorders | 1 | 2009 | 70 | 0.070 |
Why?
|
| Oxygen Radioisotopes | 2 | 2008 | 4 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 318 | 0.070 |
Why?
|
| Tic Disorders | 1 | 2009 | 84 | 0.070 |
Why?
|
| Schizophrenic Psychology | 1 | 2008 | 83 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 741 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 394 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2012 | 678 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2009 | 750 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2008 | 183 | 0.060 |
Why?
|
| Alleles | 1 | 2011 | 1709 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2012 | 1344 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 1487 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2008 | 389 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 2782 | 0.060 |
Why?
|
| Genotype | 1 | 2011 | 2655 | 0.060 |
Why?
|
| Restraint, Physical | 1 | 2025 | 31 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 331 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 28839 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1557 | 0.050 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.050 |
Why?
|
| Testosterone | 1 | 2010 | 603 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2005 | 220 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6916 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2008 | 565 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 36 | 0.050 |
Why?
|
| Thinking | 1 | 2003 | 34 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 26 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1264 | 0.050 |
Why?
|
| Acceleration | 1 | 2023 | 24 | 0.050 |
Why?
|
| Awareness | 1 | 2003 | 81 | 0.050 |
Why?
|
| Aripiprazole | 2 | 2013 | 23 | 0.050 |
Why?
|
| Water | 1 | 2003 | 190 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 440 | 0.050 |
Why?
|
| Self Concept | 1 | 2003 | 163 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2003 | 197 | 0.050 |
Why?
|
| Social Behavior | 1 | 2003 | 217 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 285 | 0.040 |
Why?
|
| Resistin | 1 | 2021 | 30 | 0.040 |
Why?
|
| Cholesterol | 1 | 2023 | 541 | 0.040 |
Why?
|
| Nerve Net | 1 | 2003 | 268 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1393 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2020 | 58 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 816 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 39 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 375 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 64 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 642 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3411 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 865 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 463 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1233 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 13300 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2019 | 562 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 184 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2013 | 181 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 232 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 342 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 4037 | 0.020 |
Why?
|
| Control Groups | 1 | 2008 | 11 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2008 | 49 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 100 | 0.020 |
Why?
|
| Reading | 1 | 2008 | 78 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2870 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 295 | 0.020 |
Why?
|
| Aged | 1 | 2004 | 21238 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 487 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 995 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7572 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8589 | 0.010 |
Why?
|